AP NEWS

Global Breast Cancer Therapeutics Market Forecast to 2023; Led by AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer - ResearchAndMarkets.com

January 4, 2019

DUBLIN--(BUSINESS WIRE)--Jan 4, 2019--The “Global Breast Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The breast cancer therapeutics market will register a CAGR of close to 8% by 2023.

Emerging novel therapies to gain traction in the market

Therapies including combination therapies, vaccines, PARP inhibitors, and CDK inhibitors are emerging as innovative approaches to treat breasts cancer.

Rising number of patient supportive initiatives

To address the economic and emotional burden associated with cancer, manufacturers, governments, non-profit organizations, and healthcare providers are aiming at improving patient access to resources and bridge the substantial gaps in care.

Tendency of patients to prefer substitutes

Individuals with breast cancer often opt for mastectomy, lumpectomy, and radiation therapy to eliminate the tumor mass. However, efficient therapies including chemotherapy, and targeted and hormonal therapies are used to treat breast cancer. These surgeries act as substitutes and patients prefer these substitutes, which are expensive and can have a series of side effects.

Key Players

AstraZeneca Eli Lilly F. Hoffmann-La Roche Novartis Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

Market definition Market sizing 2018 Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product Comparison by product Targeted therapy - Market size and forecast 2018-2023 Hormonal therapy - Market size and forecast 2018-2023 Chemotherapy - Market size and forecast 2018-2023 Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

Ductal carcinoma in situ Invasive Ductal Carcinoma Triple-negative breast cancer Inflammatory breast cancer Metastatic breast cancer

PART 10: GEOGRAPHIC LANDSCAPE

Geographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview Landscape disruption

PART 14: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AstraZeneca Eli Lilly F. Hoffmann-La Roche Novartis Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/vc65jq/global_breast?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190104005406/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Breast Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/04/2019 11:44 AM/DISC: 01/04/2019 11:44 AM

http://www.businesswire.com/news/home/20190104005406/en

AP RADIO
Update hourly